You are here:
Zepatier
Extension of indication to include treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30kg for Zepatier.
No estimate possible yet
Registration application pending
Elbasvir / grazoprevir
Infectious diseases
Indication extension
Viral infections other
MSD
Virus inhibitor
Oral
Tablet
Extramural (GVS)
Centralised (EMA)
No
March 2021
January 2022
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines